38529039|t|Therapeutic potential to target sialylation and SIGLECs in neurodegenerative and psychiatric diseases.
38529039|a|Sialic acids, commonly found as the terminal carbohydrate on the glycocalyx of mammalian cells, are pivotal checkpoint inhibitors of the innate immune system, particularly within the central nervous system (CNS). Sialic acid-binding immunoglobulin-like lectins (SIGLECs) expressed on microglia are key players in maintaining microglial homeostasis by recognizing intact sialylation. The finely balanced sialic acid-SIGLEC system ensures the prevention of excessive and detrimental immune responses in the CNS. However, loss of sialylation and SIGLEC receptor dysfunctions contribute to several chronic CNS diseases. Genetic variants of SIGLEC3/CD33, SIGLEC11, and SIGLEC14 have been associated with neurodegenerative diseases such as Alzheimer's disease, while sialyltransferase ST8SIA2 and SIGLEC4/MAG have been linked to psychiatric diseases such as schizophrenia, bipolar disorders, and autism spectrum disorders. Consequently, immune-modulatory functions of polysialic acids and SIGLEC binding antibodies have been exploited experimentally in animal models of Alzheimer's disease and inflammation-induced CNS tissue damage, including retinal damage. While the potential of these therapeutic approaches is evident, only a few therapies to target either sialylation or SIGLEC receptors have been tested in patient clinical trials. Here, we provide an overview of the critical role played by the sialic acid-SIGLEC axis in shaping microglial activation and function within the context of neurodegeneration and synaptopathies and discuss the current landscape of therapies that target sialylation or SIGLECs.
38529039	59	101	neurodegenerative and psychiatric diseases	Disease	MESH:D019636
38529039	103	115	Sialic acids	Chemical	MESH:D012794
38529039	148	160	carbohydrate	Chemical	MESH:D002241
38529039	506	517	sialic acid	Chemical	MESH:D019158
38529039	705	717	CNS diseases	Disease	MESH:D002493
38529039	739	746	SIGLEC3	Gene	945
38529039	747	751	CD33	Gene	945
38529039	753	761	SIGLEC11	Gene	114132
38529039	767	775	SIGLEC14	Gene	100049587
38529039	802	828	neurodegenerative diseases	Disease	MESH:D019636
38529039	837	856	Alzheimer's disease	Disease	MESH:D000544
38529039	864	881	sialyltransferase	Gene	84620
38529039	882	889	ST8SIA2	Gene	8128
38529039	902	905	MAG	Gene	4099
38529039	926	946	psychiatric diseases	Disease	MESH:D001523
38529039	955	968	schizophrenia	Disease	MESH:D012559
38529039	970	987	bipolar disorders	Disease	MESH:D001714
38529039	993	1018	autism spectrum disorders	Disease	MESH:D000067877
38529039	1065	1081	polysialic acids	Chemical	MESH:C021319
38529039	1167	1186	Alzheimer's disease	Disease	MESH:D000544
38529039	1191	1203	inflammation	Disease	MESH:D007249
38529039	1212	1229	CNS tissue damage	Disease	MESH:D002493
38529039	1241	1255	retinal damage	Disease	MESH:D012164
38529039	1411	1418	patient	Species	9606
38529039	1500	1511	sialic acid	Chemical	MESH:D019158
38529039	1592	1609	neurodegeneration	Disease	MESH:D019636
38529039	1614	1628	synaptopathies	Disease	
38529039	Association	MESH:D000544	114132
38529039	Association	MESH:D012559	84620
38529039	Association	MESH:D001714	84620
38529039	Association	MESH:D000544	100049587
38529039	Association	MESH:D019158	MESH:D019636
38529039	Association	MESH:C021319	MESH:D012164
38529039	Association	MESH:D000067877	4099
38529039	Association	MESH:C021319	MESH:D002493
38529039	Association	MESH:D001714	8128
38529039	Association	MESH:D019636	945
38529039	Association	MESH:D001714	4099
38529039	Association	MESH:D001523	84620
38529039	Association	MESH:D001523	4099
38529039	Association	MESH:C021319	MESH:D000544
38529039	Association	MESH:C021319	MESH:D007249
38529039	Association	MESH:D000544	945
38529039	Association	MESH:D012559	8128
38529039	Association	MESH:D019636	100049587
38529039	Association	MESH:D000067877	84620
38529039	Association	MESH:D000067877	8128
38529039	Association	MESH:D012559	4099
38529039	Association	MESH:D001523	8128
38529039	Association	MESH:D019636	114132

